Aziyo Biologics, Inc. provided sales guidance for the year 2022. For the year, the company expects total net sales for the full year 2022 will be in the range of $47 million to $50 million. Excluding approximately $4.9 million of FiberCel sales in 2021, this range represents expected growth of 11% to 18%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +0.93% | -.--% | +50.46% |
05-09 | Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.46% | 78.41M | |
-2.29% | 89.38B | |
-3.95% | 37.92B | |
-13.07% | 32.04B | |
+63.05% | 26.03B | |
-22.14% | 14.14B | |
-7.96% | 12.88B | |
-9.33% | 11.77B | |
-46.33% | 10.85B | |
+5.77% | 8.92B |
- Stock Market
- Equities
- ELUT Stock
- News Elutia Inc.
- Aziyo Biologics, Inc. Provides Sales Guidance for the Year 2022